<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03184324</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP14012002</org_study_id>
    <nct_id>NCT03184324</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Active-controlled, Phase 2, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of DWP14012 compared to
      esomeprazole in the treatment of erosive gastroesophageal reflux disease classified as Los
      Angeles(LA) classification grades A to D.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of subjects who were completely cured of mucosal defects by 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of subjects who were completely cured of mucosal defects by 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Erosive Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>DWP14012 Amg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Amg, tablet, orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWP14012 Bmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Bmg, tablet, orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWP14012 Cmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Cmg, tablet, orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomerpazole 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomerpazole 40mg, tablet, orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012</intervention_name>
    <description>tablet</description>
    <arm_group_label>DWP14012 Amg</arm_group_label>
    <arm_group_label>DWP14012 Bmg</arm_group_label>
    <arm_group_label>DWP14012 Cmg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>tablet</description>
    <arm_group_label>Esomerpazole 40mg</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 placebo</intervention_name>
    <description>tablet</description>
    <arm_group_label>DWP14012 Amg</arm_group_label>
    <arm_group_label>DWP14012 Bmg</arm_group_label>
    <arm_group_label>DWP14012 Cmg</arm_group_label>
    <arm_group_label>Esomerpazole 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole placebo</intervention_name>
    <description>tablet</description>
    <arm_group_label>DWP14012 Amg</arm_group_label>
    <arm_group_label>DWP14012 Bmg</arm_group_label>
    <arm_group_label>DWP14012 Cmg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults between 20 and 75 years old based on the date of written agreement

          -  Those who have been diagnosed with erosive gastroesophageal reflux disease(EGRD) of LA
             Grade A-D on the upper gastrointestinal endoscopy

          -  Those who experienced symptoms of heartburn or acid reflux within the last 7 days

        Exclusion Criteria:

          -  Those who have undergone gastric acid suppression or gastric, esophageal surgery

          -  Those who with clinically significant liver, kidney, nervous system, respiratory,
             endocrine, hematologic, cardiovascular, urinary system disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oh-Young Lee, M.D., Ph.D.</last_name>
    <phone>82-2-2290-8637</phone>
    <email>leeoy@hanyang.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Sungdogu</city>
        <state>Seoul</state>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oh-young Lee, M.D., Ph.D.</last_name>
      <phone>82-2-2290-8637</phone>
      <email>leeoy@hanyang.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

